Show simple item record

dc.contributor.authorSarink, Danja
dc.contributor.authorSchock, Helena
dc.contributor.authorJohnson, Theron
dc.contributor.authorOvervad, Kim
dc.contributor.authorHolm, Marianne
dc.contributor.authorTjønneland, Anne
dc.contributor.authorBoutron-Ruault, Marie-Christine
dc.contributor.authorHis, Mathilde
dc.contributor.authorKvaskoff, Marina
dc.contributor.authorBoeing, Heiner
dc.contributor.authorLagiou, Pagona
dc.contributor.authorPapatesta, Eleni-Maria
dc.contributor.authorTrichopoulou, Antonia
dc.contributor.authorPalli, Domenico
dc.contributor.authorPala, Valeria
dc.contributor.authorMattiello, Amalia
dc.contributor.authorTumino, Rosario
dc.contributor.authorSacerdote, Carlotta
dc.contributor.authorBueno-De-Mesquita, Hendrik Bastiaan
dc.contributor.authorvan Gils, Carla H.
dc.contributor.authorPeeters, Petra H.
dc.contributor.authorWeiderpass, Elisabete
dc.contributor.authorAgudo, Antonio
dc.contributor.authorSánchez, María-José
dc.contributor.authorChirlaque, Maria-Dolores
dc.contributor.authorArdanaz, Eva
dc.contributor.authorAmiano, Pilar
dc.contributor.authorKhaw, Kay Tee
dc.contributor.authorTravis, Ruth
dc.contributor.authorDossus, Laure
dc.contributor.authorGunter, Mark
dc.contributor.authorRinaldi, Sabina
dc.contributor.authorMerritt, Melissa
dc.contributor.authorRiboli, Elio
dc.contributor.authorKaaks, Rudolf
dc.contributor.authorFortner, Renée T.
dc.date.accessioned2018-02-01T12:19:53Z
dc.date.available2018-02-01T12:19:53Z
dc.date.issued2017-08-31
dc.description.abstractReceptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case–control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1,976 incident invasive breast cancer cases [estrogen receptor positive (ER+), n = 1,598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and 95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status (Phet = 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast cancer [5th vs. 1st quintile RR 1.28 (95% CI, 1.01–1.63); Ptrend = 0.20], but not ER− disease. For both ER+ and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse association between the ratio and ER−PR− disease [5th vs. 1st quintile RR = 0.60 (0.31–1.14); Ptrend = 0.03]. This study provides the first large-scale prospective data on circulating sRANKL and breast cancer. We observed limited evidence for an association between sRANKL and breast cancer risk.en_US
dc.descriptionAccepted manuscript version. Published version available in <a href=http://dx.doi.org/10.1158/1940-6207.CAPR-17-0125> Cancer Prevention Research, September 1 2017 (10) (9) 525-534</a>en_US
dc.identifier.citationSarink, D., Schock, H., Johnson, T., Overvad, K., Holm, M., Tjønneland, A., ... Fortner, R.T. (2017). Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort. Cancer Prevention Research. 2017;10(9):525-534en_US
dc.identifier.cristinIDFRIDAID 1515114
dc.identifier.doi10.1158/1940-6207.CAPR-17-0125
dc.identifier.issn1940-6207
dc.identifier.issn1940-6215
dc.identifier.urihttps://hdl.handle.net/10037/12073
dc.language.isoengen_US
dc.publisherAmerican Association for Cancer Researchen_US
dc.relation.journalCancer Prevention Research
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.titleCirculating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort.en_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record